Lymphoma is a cancer of the lymphatic system. Hodgkin disease (HD) and non-Hodgkin lymphoma are the two types of lymphomas. HD also called Hodgkin lymphoma is distinguished by the presence of large abnormal cells, called Reed-Sternberg cells. The disease is less common than non-Hodgkin lymphoma.
HD is classified into two main types:
HD is considered one of the most curable forms of cancer, especially if it is diagnosed and treated early. Five-year survival rates for people diagnosed with stage I or stage II HD are 85% to 90%. Many people with late-stage HD also have good odds for survival.
HD occurs most often in people ages 15 to 40 (especially in their 20s), and in people over age 55. About 10% to 15% of HD cases are diagnosed in children and teenagers. It is slightly more common in males than in females.
Certain types of viral infections may increase the risk for HD. Infectious mononucleosis, which is caused by the Epstein-Barr virus, is associated with increased risk as is infection with the human immunodeficiency virus (HIV).
Chemotherapy and radiation are the main treatments for HD. People who have relapsed may be treated with autologous stem cell transplantation, a procedure which uses the person's own blood cells.
Both chemotherapy and stem cell transplants increase the risk for serious infections. People who undergo these procedures must take precautions to avoid exposure to germs. Ways to prevent infections include:
Hodgkin disease (HD) is a type of lymphoma. Lymphomas are cancers of the lymphatic system. They are generally subdivided into two groups: HD and non-Hodgkin lymphoma (NHL). HD is also called Hodgkin lymphoma.
The lymphatic system filters fluid from around cells. It is an important part of the immune system. When people talk about swollen glands in the neck, they are usually referring to enlarged lymph nodes. Common areas where lymph nodes can be easily felt, especially if enlarged, are: the groin (femoral or inguinal), armpits (axillary), above the clavicle (supraclavicular), in the neck (cervical), and the back of the head just above hairline (occipital).
HD is marked by the presence of abnormal large cells called Reed-Sternberg cells. Reed-Sternberg cells are derived from B cell lymphocytes (white blood cells). Reed-Sternberg cells are specific to HD. They are not found in non-Hodgkin lymphoma.
HD often starts in B cell lymphocytes located in lymph nodes in the neck area, although any lymph node may be the site of initial disease.
There are two main types of HD:
Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma accounts for about 92% to 97% of HD cases. It has four major subtypes:
Nodular Lymphocyte-Predominant HD
Nodular lymphocyte-predominant HD occurs in about 3% to 8% of cases. It is distinct from classical Hodgkin lymphoma. The cells look alike and are referred to as "popcorn" cells, which are variants of Reed-Sternberg cells. This type of HD typically affects younger people and usually originates in the neck lymph nodes. It is sometimes confused with non-Hodgkin lymphoma (NHL). In fact, there is a 3% to 5% risk that nodular lymphocyte-predominant HD can transform into diffuse large B-cell NHL.
Lymphomas are tumors of the lymphatic system. This system is a network of organs, ducts, and nodes. The lymphatic system transports a watery clear fluid called lymph throughout the body. The lymphatic system contains lymphocytes, which are important cells involved in defending the body against infections.
Lymphocytes are a type of white blood cell. They are an essential part of the immune system:
Lymphatic vessels begin as tiny tubes. These tubes collect and carry fluids that leak from body tissues, lymphocytes, proteins, and other substances from various body tissues. The tubes lead to larger lymphatic ducts and branches, which drain into two ducts in the neck, where the fluid re-enters the bloodstream.
Along the way, the fluid passes through lymph nodes, which are oval structures made up of lymph vessels, connective tissue, and white blood cells:
Other Structures in the Lymphatic System
The tonsils and adenoids are secondary lymphatic organs. They are composed of masses of lymph tissue that also play a role in the lymphatic system. The spleen is another important organ that processes lymphocytes from incoming blood.
Spread of Cancer
Tumor cells can enter the lymph fluid and travel to the lymph nodes. HD usually progresses in an orderly way from one lymph node region to the next. This process may be slow, particularly in younger people, or very rapid. The disease typically spreads downward from the initial site:
HD is less common than non-Hodgkin lymphoma. It accounts for about 10% of all lymphomas. According to the American Cancer Society, about 9,000 new cases of HD are diagnosed in the United States each year. According to a 2012 World Health Organization report, Hodgkin lymphoma accounts for about 0.5% of all new cancers diagnosed yearly worldwide, excluding non-melanoma skin cancer.
The exact causes of HD are unknown. Research indicates that the malignant process leading to HD may be triggered by a combination of environmental and genetic factors along with a susceptible immune system.
HD occurs most often in people ages 15 to 40 (especially in their 20s), and in people over age 55. About 10% to 15% of HD cases are diagnosed in children and teenagers.
HD is slightly more common among males than females. Women who get HD may have a slightly lower risk for relapse after treatment than men.
Infectious mononucleosis ("mono"), which is caused by the Epstein-Barr virus (EBV), is linked with increased risk for HD. In a subset of HD cases, EBV genetic material is found within tumor Reed-Sternberg cells. EBV is present in 90% of all people and, in the great majority of these cases, the virus causes a mild case of mononucleosis or no illness at all. Only a very small percentage of people who have had mononucleosis develop HD. Other factors must be present to trigger the malignancy.
People infected with the human immunodeficiency virus (HIV), which weakens the immune system, are also at increased risk of developing HD.
A family history of Hodgkin lymphoma is associated with a slightly higher risk for this disease. First-degree relatives of people with HD have a 3 times higher risk than the general population. The risk is almost 100 times higher for an identical twin of a person with HD.
Symptoms of HD may include:
The last three symptoms (weight loss, fever, and night sweats) are classified as "B symptoms." B symptoms are used in staging HD and can indicate that more aggressive treatment will be required.
Sometimes people with HD do not experience any symptoms, or symptoms may not appear until the cancer is very advanced. Enlarged lymph nodes can also be caused by many noncancerous conditions, such as infections.
The health care provider will take a medical history and perform a physical examination. If these procedures indicate HD, a number of additional tests may be needed to either rule out other diseases or confirm HD and determine the extent of the cancer.
The provider will examine not only the affected lymph nodes but also the surrounding tissues and other lymph node areas for signs of infection, skin injuries, or tumors. The consistency of the node is evaluated. For example, a stony, hard node is often a sign of cancer, usually one that has metastasized (spread to another part of the body). A firm, rubbery node may indicate lymphoma (including Hodgkin). Soft tender nodes suggest infection or inflammatory conditions.
Blood tests are performed to measure white and red blood cells, blood protein levels, the uric acid level, blood proteins, and the liver's function.
A chest x-ray may show lymph nodes in the chest, where HD usually starts. It is a useful step for detecting enlarged lymph nodes.
Computed Tomography (CT)
CT scans are much more accurate than x-rays. They can detect abnormalities in the chest and neck area, as well as revealing the extent of the cancer and whether it has spread. CT scans are used to evaluate symptoms and help diagnose lymphomas, help with staging of the disease, and monitor response to treatment. A CT scan is also often used to detect lymphomas in the abdominal and pelvic areas, the brain, and chest area.
Positron Emission Tomography (PET)
PET scans combined with CT scans can help in clarifying the location of the cancer. PET scans can also provide information on whether or not an enlarged lymph node is benign or cancerous and can be used for staging lymphomas. PET scans may also help determine treatment response, if any residual cancer exists, and if a person has achieved remission.
A biopsy of the suspicious lymph node is the definitive way to diagnose HD. The lymph node sample will be examined by a pathologist for the presence of Reed-Sternberg cells or other abnormal features.
The type of biopsy performed depends in part on the location and accessibility of the lymph node. The surgeon may remove the entire lymph node (excisional biopsy) or a small part of it (incisional biopsy). In some cases, fine needle aspiration is used to withdraw a small amount of tissue from the lymph node. Biopsies of bone marrow may also be performed in people with existing HD to see if the cancer has spread to the bone marrow.
HD is considered one of the most curable forms of cancer, especially if it is diagnosed and treated early. Unlike other cancers, HD is even potentially curable in late stages.
People diagnosed with stage I or stage II HD have a very high likelihood of complete and permanent remission.
For people with more advanced or higher stage disease, prognosis worsens based on how many of the following clinical findings are present.
Outlook tends to be poorer for people who do not respond to first-line therapy or who relapse within a year of treatment. People who survive 15 years after treatment are more likely to later die from other causes than from HD.
The good news about HD is that treatment can cure the disease. The bad news is that survivors face a higher than average risk for long-term complications of these treatments, some very serious.
Many people experience chronic fatigue that can sometimes last for years. The most serious complications are secondary cancers and heart disease, which may develop over the 20 to 30 years following treatments.
Secondary cancers include non-Hodgkin lymphoma, leukemia, melanoma, stomach and lung cancers, and breast and uterine cancers. Heart disease complications include coronary artery disease, stroke, heart valve problems, and cardiomyopathy (weakening of the heart muscle). Thyroid and other endocrine disorders are also a potential complication. Combinations of radiation and chemotherapies pose the highest risk for these problems.
Studies of adult survivors of various childhood cancers have found that 30 years after treatment, people with cured HD are especially likely to have other serious health problems. Female survivors face a significantly greater risk than male survivors. In particular, women who received chest radiation are at very high risk for developing breast cancer.
People with HD should get a written record of the treatments they received as children, and the potential risks for these treatments. These records can help the providers who later oversee their care monitor for potential health problems.
Survivors of HD should receive regular screening tests for cancer and heart disease. They may need to get these tests at a younger age than most people. In particular, people who were treated with chest radiation should consider getting blood tests every 5 years to measure their cholesterol levels. Women who received chest radiation should be sure to get regular mammograms and breast magnetic resonance imaging (MRI).
Treatment options for HD depend on:
Certain factors may determine whether more intensive treatment is required. For example, the presence of B symptoms and "bulky" (large mass) tumors usually indicates a more aggressive treatment approach.
Chemotherapy and radiation are the main treatments for HD. Stem cell transplantation or a biologic drug may be recommended for people whose cancer has recurred.
HD is staged (I through IV) depending on how far the cancer has spread. Staging is the primary method for determining both treatment options and prognosis.
Stage I: Disease is limited to a single node region or has involved one neighboring area or a single nearby organ.
Stage II: Disease is limited to two or more lymph nodes on the same side of (above or below) the diaphragm or extends locally from the lymph node into a nearby organ.
Stage III: Disease is in lymph nodes on both sides of the diaphragm or has spread to nearby organs, the spleen, or both.
Stage IV: Disease has become widespread involving organs outside the lymph system, such as liver, lung, or bone marrow.
Early Stages (I or II)
HD in stages I or II may be treated with radiation therapy alone, a combination of chemotherapy and radiation therapy, or chemotherapy alone.
Later Stages (III and IV)
HD in stages III and IV is usually treated with chemotherapy alone. Radiation therapy, when recommended, is generally used due to large tumor masses (> 10 cm).
Refractory and Relapsed Hodgkin
Treatment is considered successful when the signs and symptoms of cancer disappear. This is referred to as remission. Cancer that does not respond to treatment is called refractory or resistant. Cancer that recurs after remission is called relapsed.
Treatments for refractory or relapsed Hodgkin include high dose chemotherapy with stem cell transplantation. People who are not good candidates for transplantation or who have not been helped by it may benefit from treatment with the biologic drug brentuximab (Adcetris).
Both the disease and some of the treatments suppress the immune system, increasing the risk for infections. Widespread, life-threatening infection is a particular danger if the spleen has been removed and both radiation and chemotherapy are administered. People with HD who have had a splenectomy should be vaccinated against pneumococcus, meningococcus, and Haemophilus influenza bacteria before receiving treatment.
If you may wish to have children in the future, you should ask your cancer team about fertility-preserving treatments. It is very important to have these discussions before cancer treatment starts. The American Society for Clinical Oncology (ASCO) has guidelines for the best fertility preservation methods for males and females with cancer. For men, ASCO recommends banking and freezing sperm (sperm cryopreservation) for later use in assisted reproductive therapies.
For women, egg (oocyte) cryopreservation is recommended. This procedure involves harvesting and freezing a woman's eggs (oocytes), and can be followed by in vitro fertilization and freezing of embryos for later use. It requires several weeks of pre-treatment with ovarian stimulation drugs, so timing is very important. For women who will receive radiation therapy to the pelvic region, a surgical procedure that moves the ovaries out of the path of radiation (ovarian transposition) can also help preserve fertility.
Relapse of HD is not uncommon, even after treatment for early stages. It can occur a decade or more after treatment. Relapse can occur in early-stage disease, probably because the limited radiation normally used in such cases does not destroy the disease outside of the area irradiated. People who had large tumors in the chest are also at higher risk for recurrence.
Periodic examinations and imaging tests are necessary for years after treatment, both to check for signs of relapse as well as to monitor the long-term effects of treatments.
Because HD often occurs in younger adults, diagnosis during pregnancy is of particular concern. Therapy must be effective enough to protect the mother without hurting the fetus. Chemotherapy is rarely used early in the term, because it poses a risk for birth defects.
Treatment choice must be individualized, taking into consideration the mother's wishes, the severity and pace of the disease, and the remaining length of the pregnancy. The treatment plan may need to be changed as the pregnancy progresses. If the disease develops in the second half of the pregnancy, it may be possible to postpone chemotherapy or radiation therapy until after an early induced delivery.
Chemotherapy is often the first treatment for all stages of HD. Chemotherapy uses drugs to kill cancer cells. The drugs are called cytotoxic (toxic to cells) medications. Chemotherapy is considered a systemic therapy because the drugs affect cells throughout the body.
Chemotherapy drugs may be taken by mouth as pills or given by injection or infusion. Treatment may be administered at a medical center, outpatient infusion center, medical office, or even at home. Some people receiving chemotherapy may need to remain in the hospital for several days so the effects of the drugs can be monitored.
People typically receive 2 to 6 cycles of chemotherapy, depending on the stage. A cycle is usually several weeks and consists of several doses of drug administration followed by a period of rest.
Several chemotherapy regimens are used for treating HD. Standard regimens include ABVD, Stanford V, and BEACOPP.
ABVD is used to treat adults and children in both early and late stages of HD. For early stages (I and II), people typically receive 2 (28 DAY) cycles of the drugs, followed by radiation. In late stages (III and IV), people receive 6 to 8 cycles of chemotherapy. ABVD consists of a 4-drug combination:
Stanford V consists of a 7-drug combination often given with radiation:
BEACOPP is a chemotherapy regimen reserved for late-stage HD. It is effective but can increase risk for developing secondary cancers such as leukemia. People who are treated with BEACOPP should receive long-term follow-up care to monitor for side effects from this therapy. BEACOPP consists of 7 drugs:
Brentuximab (Adcetris) is a newer biologic drug that may be used by itself. It is approved for people with HD who have either:
Brentuximab works by targeting CD-30, a protein found on Hodgkin cancer cells. The drug is given by intravenous infusion. The most common side effects are neutropenia, peripheral sensory neuropathy, fatigue, nausea, and anemia. A more serious but rare side effect is the brain disorder progressive multifocal leukoencephalopathy (PML).
In 2016, FDA approved nivolumab (Opdivo) for the treatment of classic HD in people who have:
In 2017, FDA approved pembrolizumab (KEYTRUDA) for patients who have:
Pembrolizumab has been approved for both pediatric and adult patients. Previously this drug was approved for unresectable or metastatic melanoma.
Side effects and complications of any chemotherapeutic regimen are common, more severe with higher doses, and increase over the course of treatment.
Common Side Effects of chemotherapy include:
Serious Side Effects
Serious side effects can also occur and may vary depending on the specific drugs used. They include:
Some side effects of chemotherapy may linger after treatment or may develop long after the treatment has ended. Be sure to discuss with your provider what tests you may need to monitor the long-term effects of chemotherapy treatment. Long-term complications of chemotherapy for HD may include:
Radiation therapy, which shrinks tumors, used to be the main treatment for HD. Today, radiation therapy is mainly used to treat early stage (I or II) HD and is usually given following chemotherapy.
Involved site radiation
The preferred method of radiation therapy for treating HD. It targets only the lymph node regions that are known to have cancer, not the adjacent, uninvolved lymph node regions. Involved-site radiation is usually given after several rounds of chemotherapy.
Involved site radiation is a type of external-beam radiation therapy. You lie on a table while a machine delivers high-energy x-rays to specific targets on your body.
Extended field radiation, an older approach that targeted both the diseased lymph nodes as well as surrounding healthy lymph nodes, is no longer used.
Providers are working on refining radiation therapies for HD so that they more precisely target the affected lymph nodes and deliver the lowest possible effective dose of radiation. The aim is to destroy the cancerous cells while minimizing the damage to healthy cells and causing fewer side effects.
Newer radiation techniques for HD include involved node radiation therapy, involved site radiation therapy, intensity modulated radiation therapy, and proton therapy.
Fatigue, nausea, diarrhea, dry mouth, skin irritation, and increased risk for infections are common short-term side effects of radiation therapy. These side effects generally go away after treatment is completed.
Radiation therapy can cause more serious long-term complications, which is why researchers are working on techniques to reduce the radiation doses and increase the accuracy of the beams. These complications generally depend on the radiation target site in the body. They include:
Relapsed or resistant HD is sometimes treated with high-dose chemotherapy followed by stem cell transplantation. This approach allows a person to receive higher doses of chemotherapy than could normally be used.
Transplantation involves removal and replacement of stem cells, which are produced in the bone marrow. Stem cells are the early forms for all blood cells in the body (including red, white, and immune cells). Intensive cancer treatments harm stem cells as well as cancer cells, and so the healthy stem cells must be replaced by transplanting them.
For HD, the most common type of transplant is an autologous procedure, using the person's own stem cells. An allogeneic transplant, using cells from a donor, is more risky for people with HD and is generally used only when an autologous transplant has failed. Allogeneic transplants are sometimes used as treatments for non-Hodgkin lymphoma. They have a greater risk than autologous transplants for complications such as graft-versus-host disease.
Stem cells must first be collected in one of the following ways:
Stem cells are collected several weeks before the procedure. They are frozen and stored while the person undergoes high-dose chemotherapy. Some people receive high-dose whole body radiation therapy along with chemotherapy.
After pre-transplant therapy is completed, the frozen cells are thawed and then infused into the person, similar to a blood transfusion through a central line catheter. The infusion process takes several hours. Within a few weeks, these cells start to generate new white blood cells and then new red blood cells.
The risk for infection is greatest during the first 6 weeks following the transplant. During this period, the person is closely monitored in or out of the hospital for a few months. It takes 6 to 12 months post-transplant for a person's immune system to fully recover.
Many people develop severe herpes zoster virus infections (shingles) or have a recurrence of herpes simplex virus infections (cold sores and genital herpes). Pneumonia, cytomegalovirus, aspergillus (a type of fungus), and Pneumocystis jiroveci (a fungus) are among the most serious life-threatening infections.
It is very important that people who have stem cell transplants take precautions to avoid infections. Guidelines for infection prevention include:
Early side effects of transplantation are similar to chemotherapy and include nausea, vomiting, fatigue, mouth sores, and loss of appetite. Bleeding because of reduced platelets is a high risk during the first 4 weeks and may require transfusions. Later side effects may include fertility problems (if the ovaries are affected), thyroid gland problems (which can affect metabolism), lung damage (which can cause breathing problems), other organ damage, and bone damage.
In younger people, there is a small long-term risk for leukemia after transplantation. Chemotherapy itself increases the risk for secondary cancers. Studies suggest that transplantation after chemotherapy does not add any additional risks.
American Cancer Society. What are the key statistics about Hodgkin lymphoma? Cancer.org website. www.cancer.org/cancer/hodgkin-lymphoma/about/key-statistics.html. Updated March 28, 2017. Accessed June 8, 2017.
Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(11):1574-1583. PMID: 26541251 www.ncbi.nlm.nih.gov/pubmed/26541251.
Bartlett NL, Foyil KV. Hodgkin lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff's Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier Saunders; 2014:chap 105.
Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806-1816. PMID: 21037086 www.ncbi.nlm.nih.gov/pubmed/21037086.
Castillo JJ, Lacasce AS. Hodgkin lymphoma. In: Ferri F, ed. Ferri's Clinical Advisor 2017. Philadelphia, PA: Elsevier; 2017:603-606.
Connors JM. Hodgkin lymphoma. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 186.
Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652. PMID: 20818855 www.ncbi.nlm.nih.gov/pubmed/20818855.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998;339(21):1506-1514. PMID: 9819449 www.ncbi.nlm.nih.gov/pubmed/9819449.
Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-2510. PMID: 23715580 www.ncbi.nlm.nih.gov/pubmed/23715580.
Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862. PMID: 25796459 www.ncbi.nlm.nih.gov/pubmed/25796459.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Updated March 1, 2017. Accessed April 18, 2017.
Ng AK, van Leeuwen FE. Hodgkin lymphoma: late effects of treatment and guidelines for surveillance. Semin Hematol. 2016;53(3):209-215. PMID: 27496313 www.ncbi.nlm.nih.gov/pubmed/27496313.
Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;(6):CD009411. PMID: 23784872 www.ncbi.nlm.nih.gov/pubmed/23784872.
Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet. 2012;380(9844):836-847. PMID: 22835602 www.ncbi.nlm.nih.gov/pubmed/22835602.
US Food & Drug Administration. Nivolumab (Opdivo) for Hodgkin lymphoma. www.fda.gov/drugs/informationondrugs/approveddrugs/ucm501412.htm. Updated May 17, 2016. Accessed June 9, 2017.
US Food & Drug Administration. Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma. www.fda.gov/drugs/informationondrugs/approveddrugs/ucm546893.htm. Updated March 15, 2017. Accessed June 9, 2017.
World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. globocan.iarc.fr. Accessed June 12, 2017.
Reviewed By: Richard LoCicero, MD, private practice specializing in Hematology and Medical Oncology, Longsteet Cancer Center, Gainesville, GA. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.